Indivior (GB:INDV) has released an update.
Indivior PLC has announced that Aelis Farma’s Phase 2B clinical trial results for AEF0117, a potential treatment for Cannabis Use Disorder, did not meet its primary and secondary endpoints, leading Indivior to decide against exercising its option to license the drug at this time. The study’s failure to show a significant difference in reducing cannabis use compared to placebo highlights the challenges in treating severe cases of the disorder. This setback underscores the ongoing need to understand and develop effective treatments for substance use disorders.
For further insights into GB:INDV stock, check out TipRanks’ Stock Analysis page.
